SG11202113155XA - Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease - Google Patents

Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease

Info

Publication number
SG11202113155XA
SG11202113155XA SG11202113155XA SG11202113155XA SG11202113155XA SG 11202113155X A SG11202113155X A SG 11202113155XA SG 11202113155X A SG11202113155X A SG 11202113155XA SG 11202113155X A SG11202113155X A SG 11202113155XA SG 11202113155X A SG11202113155X A SG 11202113155XA
Authority
SG
Singapore
Prior art keywords
fibrate
treatment
pharmaceutical compositions
liver disease
fxr agonist
Prior art date
Application number
SG11202113155XA
Inventor
Leigh Macconell
Richard Pencek
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of SG11202113155XA publication Critical patent/SG11202113155XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG11202113155XA 2019-05-30 2020-05-29 Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease SG11202113155XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962854859P 2019-05-30 2019-05-30
PCT/US2020/035353 WO2020243590A1 (en) 2019-05-30 2020-05-29 Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease

Publications (1)

Publication Number Publication Date
SG11202113155XA true SG11202113155XA (en) 2021-12-30

Family

ID=71787120

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202113155XA SG11202113155XA (en) 2019-05-30 2020-05-29 Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease

Country Status (13)

Country Link
US (1) US20220226350A1 (en)
EP (1) EP3976049A1 (en)
JP (1) JP2022536060A (en)
KR (1) KR20220016146A (en)
CN (1) CN114144185A (en)
AU (1) AU2020284135A1 (en)
BR (1) BR112021024109A2 (en)
CA (1) CA3142358A1 (en)
EA (1) EA202193334A1 (en)
IL (1) IL288302A (en)
MX (1) MX2021014585A (en)
SG (1) SG11202113155XA (en)
WO (1) WO2020243590A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021006618A (en) 2018-12-05 2021-09-23 Sage Therapeutics Inc Neuroactive steroids and their methods of use.
WO2023147141A1 (en) * 2022-01-28 2023-08-03 Intercept Pharmaceuticals, Inc. Combination therapy
CN116554252A (en) * 2023-04-07 2023-08-08 华南理工大学 High-crystallinity allocholic acid and application thereof in preparation of medicines for preventing and treating cholestatic liver diseases

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US860303A (en) 1905-02-18 1907-07-16 Tea Tray Company Of Newark Horn-support.
US3262580A (en) 1964-06-23 1966-07-26 Mcdowell Wellman Eng Co Slewable gantry crane
FR1498459A (en) 1965-07-30 1968-01-08
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4058552A (en) 1969-01-31 1977-11-15 Orchimed Sa Esters of p-carbonylphenoxy-isobutyric acids
US3716583A (en) 1969-04-16 1973-02-13 Sumitomo Chemical Co Phenoxy carboxylic acid derivative
AT296986B (en) 1969-08-13 1972-03-10 Merz & Co Process for the production of new α-halophenoxy-isobutyroyl-β-nicotinoyl glycols
DE2230383C3 (en) 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarboxylic acid derivatives and processes for making the same
JPS5118954B2 (en) 1972-02-04 1976-06-14
US3948973A (en) 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
DE2308826C3 (en) 1973-02-22 1980-03-27 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren Phenoxyalkanecarboxylic acid esters of oxyalkyl theophyllines, process for their preparation and pharmaceuticals
FR2244511B1 (en) 1973-07-05 1977-07-15 Roussel Uclaf
ES488665A0 (en) 1980-02-15 1980-12-16 Especialidades Farmaco Terape PROCEDURE FOR OBTAINING A NEW ANTI-AGES-CLEROTIC COMPOUND
DE69329894T2 (en) 1992-12-08 2001-05-03 Ss Pharmaceutical Co Arylamide derivatives
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
HUP0100072A3 (en) 1997-10-27 2002-11-28 Reddys Lab Ltd Dr Phenoxazine, phenthiazine derivatives, their use in medicine; process for their preparation and pharmaceutical compositions containing them
US20030109467A1 (en) 2001-11-15 2003-06-12 Isis Pharmaceuticals Inc. Antisense modulation of human FXR expression
DE69940958D1 (en) 1998-12-23 2009-07-16 Glaxo Group Ltd DETERMINATION METHOD FOR LIGANDS OF NUCLEAR RECEPTORS
US6465258B1 (en) 1999-01-07 2002-10-15 Tularik, Inc. FXR receptor-mediated modulation cholesterol metabolism
US20020132223A1 (en) 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
DE60205891T2 (en) 2001-03-12 2006-06-22 Intercept Pharmaceuticals, Inc. STEROIDS AS AGONISTS FOR FXR
DE60131967D1 (en) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4 nuclear receptor binding compounds
US7259186B2 (en) 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
DK1734970T3 (en) 2004-03-12 2015-02-16 Intercept Pharmaceuticals Inc Treatment of fibrosis using FXR ligands
WO2006121861A2 (en) 2005-05-05 2006-11-16 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors
ITMI20050912A1 (en) 2005-05-19 2006-11-20 Erregierre Spa PROCESS OF PREPARATION OF ACIDS 3-A-YA (B) -DIDROSSI-6-A (B) -ALCHIL-5B-COLANICI
BRPI0707794A2 (en) 2006-02-14 2011-05-10 Intercept Pharmaceuticals Inc bile acid derivatives, formulations and pharmaceutical compositions, as well as use of said compounds
CA2651378C (en) 2006-05-24 2012-08-28 Eli Lilly And Company Fxr agonists
ATE460403T1 (en) 2006-05-24 2010-03-15 Lilly Co Eli COMPOUNDS AND METHODS FOR MODULATING FX RECEPTORS
JP5222846B2 (en) 2006-06-27 2013-06-26 インターセプト ファーマシューティカルズ， インコーポレイテッド Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
WO2008039829A2 (en) 2006-09-26 2008-04-03 Ironwood Pharmaceuticals, Inc. Diphenylheterocycle cholesterol absorption inhibitors
JP5399262B2 (en) 2006-12-08 2014-01-29 エグゼリクシス パテント カンパニー エルエルシー LXR and FXR modulators
US20080299118A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
US20080300235A1 (en) 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
US20090163474A1 (en) 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
KR20150022974A (en) 2012-06-19 2015-03-04 인터셉트 파마슈티컬즈, 인크. Preparation, uses and solid forms of obeticholic acid
PT2912013T (en) 2012-10-26 2018-01-03 Intercept Pharmaceuticals Inc Process for preparing bile acid derivatives
PL3360881T3 (en) 2013-05-14 2021-11-15 Intercept Pharmaceuticals, Inc. 11-hydroxyl-6-substituted-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
WO2016127019A2 (en) * 2015-02-06 2016-08-11 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
TW201718621A (en) 2015-10-07 2017-06-01 英特賽普醫藥品公司 Farnesoid X receptor modulators

Also Published As

Publication number Publication date
MX2021014585A (en) 2022-01-11
US20220226350A1 (en) 2022-07-21
EP3976049A1 (en) 2022-04-06
WO2020243590A1 (en) 2020-12-03
JP2022536060A (en) 2022-08-12
IL288302A (en) 2022-01-01
CN114144185A (en) 2022-03-04
AU2020284135A1 (en) 2022-01-06
BR112021024109A2 (en) 2022-03-22
EA202193334A1 (en) 2022-03-14
KR20220016146A (en) 2022-02-08
CA3142358A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
IL288302A (en) Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
IL283840A (en) Compositions for the delivery of therapeutic agents and methods of use and making thereof
FI3911647T3 (en) Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same
IL265970B (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
BR112013016862A2 (en) combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
IL272457A (en) Glp-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
IL274578A (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
IL280083A (en) Pharmaceutical dosage form which can be administered orally and has modified release
CL2013001164A1 (en) Composition containing s- [2 - ([[1- (2-ethylbutyl) -cyclohexyl] -carbonyl] amino) phenyl] 2-methylpropanothioate] and croscarmellose sodium; Preparation process; tablet that contains it; kit and use in the treatment and prevention of cardiovascular disorders.
EP4183391A4 (en) Pharmaceutical composition and use thereof
SG11202007117RA (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
IL282251A (en) Compositions and methods for treatment of liver disease
MA53099A (en) IVOSIDENIB FORMS AND PHARMACEUTICAL COMPOSITIONS
IL262546B (en) Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients
IL286703A (en) Ghrh or analogues thereof for use in treatment of hepatic disease
ZA202104261B (en) Combination pharmaceutical compositions and methods thereof
IL272495A (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
EP3880171C0 (en) Ibuprofen-containing oral pharmaceutical formulation
GB201817346D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of diseases
IT201600122310A1 (en) Composition for use in the treatment of bowel disorders
IL310217A (en) Pharmaceutical composition and use
IL292258A (en) Pharmaceutical compositions comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the same
GB201911821D0 (en) Compounds for use in the treatment of liver disease
EP4061408A4 (en) Compositions and methods for use in type 1 diabetes
HK1254527A1 (en) Pharmaceutical formulation and use thereof